Green Cross Medical Science Corporation (KOSDAQ:142280)
South Korea · Delayed Price · Currency is KRW 3,810.00
+15.00 (0.40%)
At close: Feb 27, 2026
KOSDAQ:142280 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Other Revenue | -0 | -0 | - | -0 | - | 0 |
| 111,118 | 103,852 | 94,011 | 113,109 | 101,675 | 113,377 | |
Revenue Growth (YoY) | 11.43% | 10.47% | -16.89% | 11.25% | -10.32% | 39.13% |
Cost of Revenue | 94,593 | 89,086 | 80,056 | 100,363 | 100,043 | 93,601 |
Gross Profit | 16,524 | 14,767 | 13,955 | 12,746 | 1,631 | 19,777 |
Selling, General & Admin | 8,751 | 8,080 | 7,708 | 10,051 | 11,399 | 11,946 |
Research & Development | 3,283 | 3,383 | 2,880 | 2,167 | 2,134 | 2,654 |
Amortization of Goodwill & Intangibles | 44.53 | 49.75 | 52.93 | 58.29 | 52.82 | 65.6 |
Other Operating Expenses | 72.23 | 75.96 | 77.02 | 95.84 | 92.43 | 70.07 |
Operating Expenses | 13,130 | 12,506 | 12,683 | 14,554 | 21,795 | 15,578 |
Operating Income | 3,395 | 2,261 | 1,272 | -1,808 | -20,164 | 4,199 |
Interest Expense | -2,654 | -2,824 | -3,309 | -2,875 | -1,172 | -466.8 |
Interest & Investment Income | 29.62 | 158.13 | 273.96 | 394.85 | 26.27 | 46 |
Currency Exchange Gain (Loss) | -0.74 | -35.14 | -14.87 | 41.89 | 53.98 | -140.66 |
Other Non Operating Income (Expenses) | 3,852 | 5,215 | 4,050 | 641.81 | 89.11 | 3,439 |
EBT Excluding Unusual Items | 4,622 | 4,774 | 2,272 | -3,605 | -21,167 | 7,076 |
Gain (Loss) on Sale of Investments | -428.89 | -428.89 | -396.55 | 650.69 | 49.98 | 34.56 |
Gain (Loss) on Sale of Assets | -12.07 | -210.98 | -9.99 | 3.55 | 8.38 | 127.23 |
Other Unusual Items | -321.09 | -738.52 | - | - | - | - |
Pretax Income | 3,860 | 3,396 | 1,865 | -2,951 | -21,108 | 7,238 |
Income Tax Expense | -1,404 | -0.51 | -11.34 | 108.07 | 29.84 | 210.74 |
Earnings From Continuing Operations | 5,264 | 3,396 | 1,877 | -3,059 | -21,138 | 7,027 |
Earnings From Discontinued Operations | - | - | - | - | - | 162.96 |
Net Income to Company | 5,264 | 3,396 | 1,877 | -3,059 | -21,138 | 7,190 |
Minority Interest in Earnings | 396.19 | 184.63 | -79.45 | -521.86 | -64.04 | -473.11 |
Net Income | 5,660 | 3,581 | 1,797 | -3,581 | -21,202 | 6,717 |
Net Income to Common | 5,660 | 3,581 | 1,797 | -3,581 | -21,202 | 6,717 |
Net Income Growth | 3670.12% | 99.25% | - | - | - | - |
Shares Outstanding (Basic) | 21 | 21 | 21 | 21 | 21 | 21 |
Shares Outstanding (Diluted) | 21 | 27 | 27 | 21 | 21 | 21 |
Shares Change (YoY) | -52.36% | -0.09% | 26.96% | 0.05% | - | 90.86% |
EPS (Basic) | 265.59 | 167.93 | 85.25 | -169.87 | -1006.40 | 318.83 |
EPS (Diluted) | 150.83 | 41.05 | 75.80 | -170.00 | -1006.40 | 318.83 |
EPS Growth | 2067.61% | -45.85% | - | - | - | - |
Free Cash Flow | -3,061 | 445.24 | -1,391 | 7,454 | -21,793 | -11,314 |
Free Cash Flow Per Share | -143.62 | 16.65 | -51.96 | 353.61 | -1034.47 | -537.04 |
Gross Margin | 14.87% | 14.22% | 14.84% | 11.27% | 1.60% | 17.44% |
Operating Margin | 3.06% | 2.18% | 1.35% | -1.60% | -19.83% | 3.70% |
Profit Margin | 5.09% | 3.45% | 1.91% | -3.17% | -20.85% | 5.92% |
Free Cash Flow Margin | -2.76% | 0.43% | -1.48% | 6.59% | -21.43% | -9.98% |
EBITDA | 7,234 | 6,047 | 5,125 | 2,299 | -16,333 | 7,361 |
EBITDA Margin | 6.51% | 5.82% | 5.45% | 2.03% | -16.06% | 6.49% |
D&A For EBITDA | 3,839 | 3,786 | 3,854 | 4,107 | 3,831 | 3,162 |
EBIT | 3,395 | 2,261 | 1,272 | -1,808 | -20,164 | 4,199 |
EBIT Margin | 3.06% | 2.18% | 1.35% | -1.60% | -19.83% | 3.70% |
Effective Tax Rate | - | - | - | - | - | 2.91% |
Advertising Expenses | - | 346.48 | 99.73 | 156.14 | 198.06 | 120.84 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.